Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME	i	MEMBER'S FIRST N	NAME:	
	view (e.g., chart notes o	r lab data, to support the	. Attach any additional documentation e authorization request). Information	
			☐ URGENT	
MEMBER INFORMATIO	N			
LAST NAME:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRTH	<del>l</del> :	
STREET ADDRESS:				
CITY:		STATE:	ZIP CODE:	
PATIENT INSURANCE I	D NUMBER:	1		
☐ MALE ☐ FEMALE	HEIGHT (IN/CM):	WEIGHT (LB/KG):	ALLERGIES:	
PATIENT'S AUTHORIZEI AUTHORIZED REPRESE	<u>IETHERAPEUTICS.CO</u> D REPRESENTATIVE (	M/NOPP  IF APPLICABLE):	CAN BE FOUND AT THE	
AUTHORIZED REPRESE	NTATIVE 3 FITONE NO	DWIDER.		
PRESCRIBER INFORMA	ATION			
LAST NAME:		FIRST NAME:		
PRESCRIBER SPECIAL	TY:	EMAIL ADDRES	EMAIL ADDRESS:	
NPI NUMBER:		DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER:		
STREET ADDRESS:		<u>'</u>		
CITY:		STATE:	ZIP CODE:	
REQUESTER (if different than prescriber):		OFFICE CONTA	OFFICE CONTACT PERSON:	
		<b>'</b>		
MEDICATION OR MEDI	CAL DISPENSING INFO	ORMATION		
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFI	QUANTITY:	
☐ NEW THERAPY	RENEWAL I	F RENEWAL: DATE TH	J.	
DURATION OF THERAP	Y (SPECIFIC DATES):			
Continued on next page				

©2017-2024 Prime Therapeutics Management LLC, a Prime Therapeutics company Prime Therapeutics Management – Commercial Clients. Revision Date: 8.15.2025 CAT009



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST N	IAME:			
1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION?  YES (if yes, complete below) NO					
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:			
2. LIST DIAGNOSES:		ICD-10:			
☐ Type II diabetes ☐ Type II diabetes with Chronic I ☐ Type II diabetes with establish ☐ Other diagnosis:					
3. REQUIRED CLINICAL INFORMATO SUPPORT A PRIOR AUTHORIS	<b>ATION:</b> PLEASE PROVIDE ALL REL ZATION.	EVANT CLINICAL INFORMATION			
Is patient going to be using drug	in combination with a clinical trial?	? ☐ Yes ☐ No			
medication 7.0% or greater?	nagliptin/metformin) ) metformin)  gliptin) ptin) tin) above medications, will concomita	A1c level required.			
medications be discontinued?   '	Yes □ No				
	with no comorbid condition listed ent currently taking metformin?				
Has treatment with metformin bed	en avoided due to lactic acidosis o	r elevated liver enzymes? □ Yes			



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:	
Is the patient's estimated glomerula Yes □ No <i>Documentation of GFR</i> I	ar filtration rate (GFR) less than or equal to 45 mL/min/1.73 m2? □ required.	
	erum creatinine level exceeding 1.8 mg/dL or an estimated GFR es □ No Documentation required.	
Does the patient have advanced live Documentation required.  If yes, please select:  Ascites Cirrhosis Hepatic encephalopathy Portal hypertension	rer disease with at least one of the following? □ Yes □ No	
Has the patient had a 3-month trial	with generic liraglutide ? □ Yes □ No <i>Documentation required.</i>	
If patient has used generic liragluti No <i>Documentation required</i> .	de, did patient reach their HbA1C goal of less than 7%?□ Yes □	
Does patient have an absolute con- required.	traindication to generic liraglutide? □ Yes □ No <i>Documentation</i>	
	rith established cardiovascular disease, answer the following: n generic liraglutide? □ Yes □ No <i>Please submit chart</i>	
Does patient have an absolute condocumentation.	traindication to liraglutide? □ Yes □ No Please submit chart	
one of the following?   History of MI or stroke or transies: History of unstable angina with E: History of coronary revasculariza: History of carotid revascularizatio: History of peripheral revascularizing: History of symptomatic coronary imaging	CG changes ation procedure on procedure	
extremities arteries □Patient has asymptomatic cardiac exercise test or stress echo or any	c ischemia documented by positive nuclear imaging test or cardiac imaging	
□Patient has chronic heart failure N □Chronic renal impairment docume renal disease(MDRD)	NYHA class II or III enter the control of the contr	



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: MEMBER'S FIRST NAME:
Is patient 60 years of age or older AND has at least 1 or more of the following risk factors?   No Please submit chart documentation.  Persistent microalbuminuria (30.299mg/g) or proteinuria  Hypertension and left ventricular hypertrophy by ECG or imaging  Left ventricular systolic or diastolic dysfunction by imaging  Ankle/brachial index less than 0.9  For the diagnosis of Type II diabetes with chronic kidney disease(CKD), please answer the following:  Has patient had chronic kidney disease for 3 or more months?   Yes   No *Please provide documentation.
Does patient have Type II diabetes? □ Yes □ No
Does patient have and estimated GFR(eGFR) greater than or equal to 50ml/min/1.73m² and less than or equal to 75ml/min/1.73m² with urinary albumin:creatinine ratio greater than or equal to 300mg/G? Yes No *Please provide documentation.  Does patient have and estimated GFR(eGFR) greater than or equal to 25 to less than 50ml/min/1.73m² with urinary albumin:creatinine ratio greater than or equal to 100mg/G Yes No *Please provide documentation.  Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?
Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.
<b>ATTESTATION:</b> I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.
Prescriber Signature or Electronic I.D. Verification: Date:
<b>CONFIDENTIALITY NOTICE:</b> The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:	

**FAX THIS FORM TO:** 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP-4201 P.O. Box 64811 St. Paul, MN 55164-0811 **Phone**: 877-228-7909

